BIG 2-97 IES
BIG 2-97 IES is a randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen.
The study found that in postmenopausal women, switching to exemestane after 2-3 years of tamoxifen significantly improves disease-free survival (New England Journal of Medicine 2004) and OS (ASCO 2006).
Coordinating group: ICCG
Start date: February 1998
Closure date: February 2003
Target nr. of patients: 4740
Final accrual: 4743
ClinicalTrials.gov Identifier: NCT00038467